Tel: +44 (0)131 339 9910 skype: murgitroyd-russell.thom
IP Due Diligence
Opposition and Appeal Proceedings
Patents (Life Sciences and Healthcare)
Expertise:Russell’s scientific background includes a degree in Medical Biochemistry from the University of Glasgow and a PhD relating to the determination of the protein structure of a number of glutathione-S-transferases to enhance herbicide selectivity.
With a core expertise within the field of biotechnology, Russell has a particular focus on peptide based therapies, nucleic acid based therapeutics, diagnostic assays and medical devices.
Russell has worked extensively with universities and small to medium sized biotechnology companies, assisting them on all aspects of the patent process. This includes the assessment of initial ideas through to the delivery of a suitable patent strategy which is optimised to achieve the commercial goals required of any particular technology.
Russell has also been extensively involved with initiatives to raise IP awareness within organisations. He routinely provides seminars, workshops and IP surgeries to academics and R&D staff to promote knowledge in relation to intellectual property. He has also worked with a number of larger organisations to develop a suitable intellectual property policy which covers all aspects of IP management from the initial capture and review of inventions, through to processes for the management of large intellectual property portfolios in order that the organisations can maximise the return they receive from their intellectual assets.
Russell joined Murgitroyd & Company in 2000 and is based in the company’s Glasgow office. He was appointed as a Director, Patents in 2008 and has a leading role in the management of the company’s life sciences team, as well as responsibility for risk management issues across the company. He also contributes regularly to www.eupatent.com, Murgitroyd & Company's sister website which details the latest developments in the European patent field.
■ Thom R. Pharmaceutical Patent Analyst. May 2012, Vol. 1, No. 2, Pages 117-119 , DOI 10.4155/ppa.12.10 (doi:10.4155/ppa.12.10)
■ Thom, R., Drug Discovery Today: TARGETS. 2004 Jun; 3, 3:123-124. Patent update.
■ Thom R, Cummins I, Dixon DP, Edwards R, Cole DJ, Lapthorn AJ. Biochemistry. 2002 Jun 4;41(22):7008-20. Structure of a tau class glutathione S-transferase from wheat active in herbicide detoxification.
■ Thom R, Dixon DP, Edwards R, Cole DJ, Lapthorn AJ. J Mol Biol. 2001 May 18;308(5):949-62. The structure of a zeta class glutathione S-transferase from Arabidopsis thaliana: characterisation of a GST with novel active-site architecture and a putative role in tyrosine catabolism.
■Thom, R, Dixon, D, Edwards, R, Cole, D, and Lapthorn, A (2001) Structure determination of zeta class glutathione transferase from Arabidopsis thaliana. Chemico-biological Interactions, 133 . pp. 53-54.
■ Lucke T, Choudhry R, Thom R, Selmer IS, Burden AD, Hodgins MB. J Invest Dermatol. 1999 Mar;112(3):354-61. Upregulation of connexin 26 is a feature of keratinocyte differentiation in hyperproliferative epidermis, vaginal epithelium, and buccal epithelium.
Qualifications:BSc Medical Biochemistry, University of Glasgow
Chartered Patent Attorney (UK)
European Patent Attorney
European Trade Mark and Design Attorney
Practice Jurisdiction(s):Europe (before European Patent Office)
Europe (before EU Trade Mark/Design Registration Office)
Running, hill walking.
Murgitroyd & Company Limited SC144082 165-169 Scotland Street, Glasgow G5 8PL, Scotland
Copyright © 2013 Murgitroyd & Company. All rights reserved. UK VAT Registration Number: GB 262 3843 59